Publications by authors named "E A Graves"
Strategies to enhance the anti-tumor immune response of stereotactic ablative radiotherapy (SABR) at primary tumors and abscopal sites are under intensive investigation. Here we report a metabolizable binary supracluster (BSC) that combines gold nanoclusters as radiosensitizing adjuvants with small interfering RNA (siRNA) targeting the immunosuppressive mediator galectin-1 (Gal-1). BSC comprises reversibly crosslinked cationic gold nanoclusters and siRNA complexes in a polymer matrix that biodegrades over weeks, facilitating clearance (90.
View Article and Find Full Text PDFArticle Synopsis
- Spastic paraplegia 47 (SPG47) results from mutations in the AP4B1 gene, leading to symptoms like progressive spastic paraplegia, developmental delays, intellectual disability, and epilepsy.
- Researchers used a gene therapy approach with a viral vector (AAV9/hAP4B1) to deliver the correct AP4B1 gene into a mouse model, successfully correcting multiple disease symptoms and restoring protein levels.
- Preclinical safety studies in non-human primates showed no major side effects, setting the stage for potential clinical trials to treat SPG47 patients.
Background: FLASH radiation therapy (RT) offers a promising avenue for the broadening of the therapeutic index. However, to leverage the full potential of FLASH in the clinical setting, an improved understanding of the biological principles involved is critical. This requires the availability of specialized equipment optimized for the delivery of conventional (CONV) and ultra-high dose rate (UHDR) irradiation for preclinical studies.
View Article and Find Full Text PDF